Skip to content

Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy

A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics for Ureteroscopy in Moderate to High Infectious Risk Population

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06149455
Enrollment
72
Registered
2023-11-29
Start date
2024-01-01
Completion date
2026-01-01
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Urinary Tract, Nephrolithiasis

Brief summary

The goal of this non-inferiority randomized controlled trial: is to test the hypothesis that the that there is no additional benefit from a longer course (7 days) versus a shorter course (2 days) of pre-operative antibiotics in patients with moderate to high risk of infection undergoing ureteroscopy. The main questions it aims to answer are: 1. Determine the safety and efficacy of a short course (2 days) as compared to a long course (7 days) 2. Identify secondary predictors of post-operative infectious complications

Detailed description

Post-operative infectious complications including urinary tract infection (UTI), systemic inflammatory response syndrome (SIRS), and sepsis are uncommon but potentially devastating complications after ureteroscopy. The clinical guidance from the American Urologic Association (AUA) and the European Association of Urology (EAU) is to provide treatment for symptomatic urinary tract infections however the management for asymptomatic patients with positive cultures or those patients who are otherwise at high risk of urinary tract colonization is unclear. As a result, there is significant practice variation in pre-operative prophylactic antibiotic prescription, even amongst fellowship trained endourologists, with some providers prescribing over ten days of pre-operative antibiotics while others offer none. This is a critical gap in our understanding of pre-operative prophylactic antibiotic utilization in a population of patients not only at higher risk of harboring multi-drug resistant (MDR) organisms but are also more susceptible to deleterious outcomes due to their frailty. Recent randomized trials have demonstrated that short courses of pre-operative antibiotics are no less protective than long courses in patients undergoing percutaneous nephrolithotomy (PCNL) for stone removal. Ureteroscopy is the most commonly performed stone surgery worldwide. Establishing an evidence-based approach for antibiotic prophylaxis in the ureteroscopic surgical patient population will be impactful for a large number of patients. The goal of this study is to implement a well-designed randomized clinical trial to establish the standardized antibiotic protocol necessary to minimize unnecessary antibiotic use which may otherwise lead to adverse reactions and proliferation of multi-drug resistant organisms.

Interventions

Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* age (greater than or equal to 18 years) * indwelling ureteral stent in place * nephrostomy tube in place * indwelling foley catheter, suprapubic catheter or clean intermittent catheterization * asymptomatic bacteriuria * bowel interposition (such as ileal conduit, neobladder) * immunosuppression (such as for transplant recipients, active chemotherapy use)

Exclusion criteria

* pregnancy * active infection * received antibiotics within 7 days preceding surgery that were not prescribed for the study

Design outcomes

Primary

MeasureTime frameDescription
infectious complication rate30 days after surgeryany occurrence of urinary tract infection, pyelonephritis, systemic inflammatory response syndrome or sepsis

Secondary

MeasureTime frameDescription
Non-infectious complications including readmission30 days after surgeryAny other complications after the surgical procedure such as pain, readmission, urinary retention, etc
Adverse reaction to antibiotic regimen2-7 days prior to surgery (depending on which arm the patient was randomized to)Any adverse reaction to antibiotic regimen
Identification of secondary markers of post-operative sepsisObtained during the peri-operative periodMarkers of infection will be drawn preoperatively including erythrocyte sedimentation rate, c-reactive protein test, intra-operative renal pelvis pressure

Countries

United States

Contacts

Primary ContactThomas Chi, MD, MBA
tom.chi@ucsf.edu415-353-2200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026